Tricyclic delta opioid modulators

Abstract

The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

1 . A method of providing analgesia comprising administering to a patient a compound of Formula (I): 
     
       
         
         
             
             
         
       
     
     wherein:
 G is —C(Z)N(R 1 )R 2 , C 6-10 aryl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, furyl, indazolyl, indolyl, indolinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, and pyridinyl; wherein aryl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkanyloxy, hydroxy(C 1-8 )alkanyl, carboxy(C 1-8 )alkanyl, C 1-g alkanylcarbonylamino, halogen, hydroxy, cyano, nitro, oxo, thioxo, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-8 alkanylthio, C 1-8 alkanylsulfonyl, C 1-8 alkanylsulfonylamino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, C 1-8 alkanylaminocarbonyl, di(C 1-8 alkanyl)aminocarbonyl, and C 1-6 alkanyloxycarbonylamino; 
 R 1  is a substituent selected from the group consisting of hydrogen, C 1-8 alkanyl, C 2-8 alkenyl, and C 2-8 alkynyl; 
 R 2  is a substituent selected from the group consisting of hydrogen; C 1-8 alkanyl; C 2-8 alkenyl; C 2-8 alkynyl; C 6-10 aryl; and C 1-8 cycloalkanyl; 
 wherein C 1-8 alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C 1-6  alkanylamino, di(C 1-6  alkanyl)amino, C 1-6  alkanyloxy, thioC 1-6 alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, C 1 -8  alkanylaminocarbonyl, di(C 1-8  alkanyl)aminocarbonyl, C 1-6 alkanyloxycarbonyl, and aryloxy; and wherein any aryl-containing substituents and C 1-8 cycloalkanyl substituents of R 2  are optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkanyloxy, trifluoromethyl, trifluoromethoxy, phenyl, halogen, cyano, hydroxy, C 1-8  alkanylthio, C 1-8  alkanylsulfonyl, and C 1-8 alkanylsulfonylamino; or R 1  and R 2  taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, hydroxy(C 1-8 )alkanyl, hydroxy, amino, C 1-6 alkanylamino, di(C 1-6  alkanyl)amino, and halogen; 
 R 3  is a substituent selected from the group consisting of hydrogen, C 1-8 alkanyl, halo 1-3 (C 1-8 )alkanyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3 -8 cycloalkanyl, cycloalkanyl(C 1-8 )alkanyl, C 1 -8 alkanyloxy(C 1-8 )alkanyl, C 1-8  alkanylthio(C 1-8 )alkanyl, hydroxyC 1 -8 alkanyl, C 1-8 alkanyloxycarbonyl, halo 1-3 (C 1-8 )alkanylcarbonyl, formyl, thioformyl, carbamimidoyl, phenylimino(C 1-8 )alkanyl, phenyl(C 1-8 )alkanyl, phenyl(C 1-8 )alkenyl, phenyl(C 1-8 )alkynyl, naphthyl(C 1-8 )alkanyl and heteroaryl(C 1-8 )alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiazolyl; wherein phenyl, naphthyl, and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyl, C 2-6  alkenyl, C 1 -6 alkanyloxy, amino, C 1 -6 alkanylamino, di(C 1-6  alkanyl)amino, C 1-6 alkanylcarbonyl, C 1-6 alkanylcarbonyloxy, C 1-6 alkanylcarbonylamino, C 1-6 alkanylthio, C 1-6 alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C 1-6 )alkanyl, thioureido, and fluoro(C 1-6 )alkanyloxy; alternatively, when phenyl and heteroaryl are optionally substituted with alkanyl or alkanyloxy substituents attached to adjacent carbon atoms, the two substituents can together form a fused cyclic alkanyl or cycloheteroalkanyl selected from the group consisting of —(CH 2 ) 3-5 —, —O(CH 2 ) 2-4 —, —(CH 2 ) 2-4 O—, and —O(CH 2 ) 1-3 O—; 
 R 4  is one to three substituents independently selected from the group consisting of hydrogen; C 1-6 alkanyl; C 2-6 alkenyl; C 2-6 alkynyl; aryl(C 2-6 )alkynyl; C 1-6 alkanyloxy; amino; C 1-6 alkanylamino; di(C 1-6 alkanyl)amino; C 6-10 arylamino wherein C 6-10 aryl is optionally substituted with one to three substitutents independently selected from the group consisting of C 1-6 alkanyl, C 1-6 alkoxy, halogen, and hydroxy; formylamino; pyridinylamino; C 1-6 alkanylcarbonyl; C 1 -6 alkanylcarbonyloxy; C 1-6 alkanyloxycarbonyl; aminocarbonyl; C 1-6 alkanylaminocarbonyl; di(C 1-6 alkanyl)aminocarbonyl; C 1 -6 alkanylcarbonylamino; C 1-6 alkanylthio; C 1-6 alkanylsulfonyl; halogen; hydroxy; cyano; hydroxycarbonyl; C 6-10 aryl; chromanyl; chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl; naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl; tetrazolyl; thiazolyl; thienyl; fluoroalkanyl and fluoroalkanyloxy; or optionally; when R 4  is two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the fused moiety is —(CH 2 ) 3-5 —, —O(CH 2 ) 2-4 —, —(CH 2 ) 2-4 O—, —O(CH 2 ) 1-3 O—, or —S—C(NH 2 )═N—; 
 R 5  is one to two substituents independently selected from the group consisting of hydrogen, C 1-6 alkanyl, C 2-6 alkenyl, C 1-6 alkanyloxy, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-6 alkanylcarbonyl, C 1-6 alkanylcarbonyloxy, C 1-6 alkanyloxycarbonyl, C 1-6 alkanylamino carbonyl, C 1-6 alkanylcarbonylamino, C 1-6 alkanylthio, C 1-6 alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C 1-6 )alkanyl and fluoro(C 1-6 )alkanyloxy; 
 A is —(CH 2 ) m —, wherein m is 2 or 3; 
 Y is O; 
 Z is O, S, NH, N(C 1-6 alkanyl), N(OH), N(OC 1-6 alkanyl), or N(phenyl); 
 
     and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof. 
   
   
       2 . The method according to  claim 1  wherein G is —C(Z)N(R 1 )R 2 , phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, C 1-8 alkanyloxy, ydroxyl(C 1-8 )alkanyl, carboxy(C 1-8 )alkanyl, C 1-8 alkanylcarbonylamino, halogen, ydroxyl, cyano, oxo, thioxo, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-8 alkanylthio, aminocarbonyl, aminothiocarbonyl, C 1-8 alkanylaminocarbonyl, di(C 1-8 alkanyl)aminocarbonyl, and C 1-6 alkanyloxycarbonylamino. 
   
   
       3 . The method according to  claim 1  wherein G is —C(Z)N(R 1 )R 2 , phenyl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, C 1-8 alkanyloxy, ydroxyl(C 1-8 )alkanyl, carboxy(C 1-8 )alkanyl, C 1-8 alkanylcarbonylamino, halogen, ydroxyl, cyano, oxo, thioxo, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-8 alkanylthio, aminocarbonyl, aminothiocarbonyl, C 1-8 alkanylaminocarbonyl, di(C 1-8 alkanyl)aminocarbonyl, and C 1-6 alkanyloxycarbonylamino. 
   
   
       4 . The method according to  claim 1  wherein G is —C(Z)N(R 1 )R 2 , phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-4 alkanyl, C 1-4 alkanyloxy, ydroxyl(C 1-4 )alkanyl, carboxy(C 1-4 )alkanyl, C 1-4 alkanylcarbonylamino, ydroxyl, cyano, oxo, thioxo, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-8 alkanylthio, aminocarbonyl, aminothiocarbonyl, C 1-8 alkanylaminocarbonyl, and di(C 1-8 alkanyl)aminocarbonyl. 
   
   
       5 . The method according to  claim 1  wherein G is —C(Z)N(R 1 )R 2 , phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, thienyl, isothiazolyl, isoxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-4 alkanyl, C 1-4 alkanyloxy, ydroxyl(C 1-4 )alkanyl, C 1-4 alkanylcarbonylamino, ydroxyl, cyano, oxo, thioxo, and aminocarbonyl. 
   
   
       6 . The method according to  claim 1  wherein G is —C(Z)N(R 1 )R 2 , phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-4 alkanyl, C 1-4 alkanyloxy, ydroxyl(C 1-4 )alkanyl, C 1-4 alkanylcarbonylamino, ydroxyl, cyano, oxo, thioxo, and aminocarbonyl. 
   
   
       7 . The method according to  claim 1  wherein G is —C(Z)N(R 1 )R 2 , tetrazolyl, pyridinyl, oxadiazolyl optionally substituted with oxo, or phenyl optionally substituted with (C 1-8 )alkanylcarbonylamino. 
   
   
       8 . The method according to  claim 1  wherein G is —C(Z)N(R 1 )R 2 , 1H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridine-3-yl or pyridine-4-yl. 
   
   
       9 . The method according to  claim 1  wherein R 1 is a substituent selected from the group consisting of hydrogen and C 1-4 alkanyl. 
   
   
       10 . The method according to  claim 1  wherein R 1  is selected from the group consisting of hydrogen, methyl, ethyl, and propyl. 
   
   
       11 . The method according to  claim 1  wherein R 1 is selected from the group consisting of hydrogen, methyl, and ethyl. 
   
   
       12 . The method according to  claim 1  wherein R 2  is selected from the group consisting of hydrogen; C 1-4 alkanyl; phenyl; and C 1-6 cycloalkanyl; wherein C 1-4 alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-4 alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, C 1-8 alkanylaminocarbonyl, di(C 1-8 alkanyl)aminocarbonyl, and phenoxy; and wherein any phenyl-containing substituents and C 1-6 cycloalkanyl substituents of R 2  are optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, C 1-8 alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, C 1-8 alkanylthio, C 1-8 alkanylsulfonyl, and C 1-8 alkanylsulfonylamino; or R 1  and R 2  taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of C 1-4 alkanyl, hydroxy(C 1-4 )alkanyl, hydroxy, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, and fluoro. 
   
   
       13 . The method according to  claim 1  wherein R 2  is selected from the group consisting of hydrogen, C 1-4 alkanyl, phenyl, and C 1-6 cycloalkanyl; wherein C 1-4 alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C 1-4 alkanyloxy, hydroxy, fluoro, aminocarbonyl, C 1-8 alkanylaminocarbonyl, di(C 1-8 alkanyl)aminocarbonyl, and phenoxy; and wherein any phenyl-containing substituent of R 2  is optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyl, C 1-6 alkanyloxy, fluoro, hydroxy, and C 1-6 alkanylthio; or R 1  and R 2  taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C 1-4 alkanyl and hydroxy. 
   
   
       14 . The method according to  claim 1  wherein R 2  is selected from the group consisting of hydrogen, C 1-4 alkanyl and phenyl; wherein C 1-4 alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C 1-4 alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R 2  is optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyl, C 1-6 alkanyloxy, fluoro, and hydroxy; or R 1  and R 2  taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C 1-3 alkanyl and hydroxy. 
   
   
       15 . The method according to  claim 1  wherein R 2  is selected from the group consisting of hydrogen and C 1-4 alkanyl; wherein C 1-4 alkanyl is optionally substituted with phenyl; or R 1  and R 2  taken together with the nitrogen to which they are attached form a pyrrolidinyl wherein said pyrrolidinyl is optionally substituted with hydroxy. 
   
   
       16 . The method according to  claim 1  wherein R 2  is selected from the group consisting of hydrogen, methyl, ethyl, and phenethyl; or R 1  and R 2  taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydoxypyrrolidin-1-yl or 3-(S)-hydoxypyrrolidin-1-yl. 
   
   
       17 . The method according to  claim 1  wherein R 3  is selected from the group consisting of hydrogen, C 1-8 alkanyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkanyloxy(C 1-8 )alkanyl, C 1-8 alkanylthio(C 1-8 )alkanyl, hydroxyC 1-8 alkanyl, thioformyl, phenylimino(C 1-8 )alkanyl, phenyl(C 1-8 )alkanyl, and heteroaryl(C 1-8 )alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from —O(CH 2 ) 1-3 O—. 
   
   
       18 . The method according to  claim 1  wherein R 3  is selected from the group consisting of hydrogen, C 1-8 alkanyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkanyloxy(C 1-8 )alkanyl, C 1-8 alkanylthio(C 1-8 )alkanyl, hydroxyC 1-8 alkanyl, thioformyl, phenylimino(C 1-8 )alkanyl, phenyl(C 1-8 )alkanyl, and heteroaryl(C 1-8 )alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, thiazolyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from —O(CH 2 ) 1-3 O—. 
   
   
       19 . The method according to  claim 1  wherein R 3  is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(C 1-8 )alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group. 
   
   
       20 . The method according to  claim 1  wherein R 3  is selected from the group consisting of hydrogen, methyl, methylbutenyl, propenyl, benzyl, phenethyl, and heteroaryl(C 1-8 )alkanyl wherein the heteroaryl is selected from the group consisting of imidazolyl, furanyl, pyridinyl, thienyl, and thiazolyl. 
   
   
       21 . The method according to  claim 1  wherein R 3  is selected from the group consisting of hydrogen, methyl, 3-methyl-2-butenyl, 2-propenyl, benzyl, 2-phenethyl, pyridin-2-ylmethyl, fur-3-ylmethyl, thiophene-2-ylmethyl, 1H-imidazol-2-ylmethyl, and thiazol-2-ylmethyl. 
   
   
       22 . The method according to  claim 1  wherein R 3  is hydrogen, methyl, allyl, or heteroarylmethyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, and thienyl. 
   
   
       23 . The method according to  claim 1  wherein R 4  is one to three substituents independently selected from the group consisting of hydrogen; C 1-6 alkanyl; C 1-6 alkanyloxy; C 6-10 arylamino wherein C 6-10 aryl is optionally substituted with one to three substitutents independently selected from the group consisting of C 1-6 alkanyl; C 1-6 alkoxy, halogen, and hydroxy; formylamino; pyridinylamino; aminocarbonyl; C 1-6 alkanylaminocarbonyl; C 1-6 alkanylcarbonylamino; halogen; hydroxy; C 6-10 aryl; chromanyl; chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl; naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl; tetrazolyl; thiazolyl; and thienyl. 
   
   
       24 . The method according to  claim 1  wherein R 4  is one to two substituents independently selected from the group consisting of hydrogen, C 1-4 alkanyl, C 1-4 alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy. 
   
   
       25 . The method according to  claim 1  wherein R 4  is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, α′- or β′-phenyl, α′- or β′-pyridinyl, α′- or β′-furanyl, and hydroxy. 
   
   
       26 . The method according to  claim 1  wherein R 4  is one to two substituents independently selected from the group consisting of hydrogen, methyl, phenyl, bromo, fluoro, methoxy, aminocarbonyl, chloro and hydroxy. 
   
   
       27 . The method according to  claim 1  wherein R 4  is hydrogen, α′-methoxy, or α′-hydroxy. 
   
   
       28 . The method according to  claim 1  wherein R 4  is hydrogen. 
   
   
       29 . The method according to  claim 1  wherein R 4  is α′-hydroxy. 
   
   
       30 . The method according to  claim 1  wherein R 5  is one to two substituents independently selected from the group consisting of hydrogen and halogen. 
   
   
       31 . The method according to  claim 1  wherein R 5  is hydrogen. 
   
   
       32 . The method according to  claim 1  wherein A is —(CH 2 ) 2-3 —. 
   
   
       33 . The method according to  claim 1  wherein A is —(CH 2 ) 2 —. 
   
   
       34 . The method according to  claim 1  wherein Z is O, NH, N(C 1-6 alkanyl), N(OH), N(OC 1-6 alkanyl), or N(phenyl). 
   
   
       35 . The method according to  claim 1  wherein Z is O, NH, or N(OH). 
   
   
       36 . The method according to  claim 1  wherein Z is O or NH. 
   
   
       37 . The method according to  claim 1  wherein
 G is —C(Z)N(R 1 )R 2 , phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, or pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, C 1-8 alkanyloxy, hydroxy(C 1-8 )alkanyl, carboxy(C 1-8 )alkanyl, C 1-8 alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-8 alkanylthio, aminocarbonyl, aminothiocarbonyl, C 1-8 alkanylaminocarbonyl, di(C 1-8 alkanyl)aminocarbonyl, and C 1-6 alkanyloxycarbonylamino;   R 1  is C 1-4 alkanyl, or hydrogen;   R 2  is hydrogen or C 1-4 alkanyl optionally substituted with phenyl;   or R 1  and R 2  taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxy;   Z is NH or oxygen;   R 3  is pyridinyl(C 1-8 )alkanyl, furyl(C 1-8 )alkanyl, C 1-8  alkanyl, hydrogen, C 2-8  alkenyl, thienyl(C 1-8 )alkanyl, imidazolyl(C 1-8 )alkanyl, phenyl(C 1-8 )alkanyl, or thiazolyl(C 1-8 )alkanyl;   R 4  is hydrogen, C 1-6 alkanyl, C 1-6 alkanyloxy, hydroxy, halogen, aminocarbonyl, or phenyl;   R 5  is hydrogen;   A is CH 2 CH 2 ;   Z is O or NH; and   
     enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts thereof. 
   
   
       38 . The method according to  claim 37  wherein G is —C(Z)N(R 1 )R 2 ; tetrazolyl; oxadiazolyl optionally substituted with oxo; furyl; quinolinyl; thienyl; phenyl optionally substituted with (C 1-8 )alkanylcarbonylamino; or pyridinyl. 
   
   
       39 . The method according to  claim 38  wherein when R 1  and R 2  taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxy, Z is oxygen 
   
   
       40 . The method according to  claim 1  wherein:
 G is —C(Z)N(R 1 )R 2 ; tetrazolyl; oxadiazolyl optionally substituted with oxo; phenyl optionally substituted with (C 1-8 )alkanylcarbonylamino; or pyridinyl;   R 1  is C 1-4  alkanyl, or hydrogen;   R 2  is hydrogen or C 1-4  alkanyl optionally substituted with phenyl;   or R 1  and R 2  taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxyl;   Z is NH or oxygen;   R 3  is pyridinyl(C 1-8 )alkanyl, furyl(C 1-8 )alkanyl, C 1-8  alkanyl, hydrogen, C 2-8  alkenyl, thienyl(C 1-8 )alkanyl, imidazolyl(C 1-8 )alkanyl, phenyl(C 1-8 )alkanyl, or thiazolyl(C 1-8 )alkanyl;   R 4  is hydrogen, α′-hydroxy, or α′-methoxy;   R 5  is hydrogen;   A is CH 2 CH 2 ;   Z is O or NH; and   enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts thereof.   
   
   
       41 . The method according to  claim 1  wherein:
 G is —C(Z)N(R 1 )R 2 , 1H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl,   R 1  is hydrogen, ethyl, or methyl,   R 2  is methyl, ethyl, phenethyl, or hydrogen;   or R 1  and R 2  taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-(S)-hydroxypyrrolidin-1-yl;   Z is NH or oxygen,   R 3  is pyridin-2-ylmethyl, fur-3-ylmethyl, methyl, hydrogen, 3-methyl-2-butenyl, thiophene-2-ylmethyl, 2-propenyl, 1H-imidazol-2-ylmethyl, 2-phenethyl, thiazol-2-ylmethyl, benzyl,   R 4  is hydrogen, α′-methoxy, or α′-hydroxy,   R 5  is hydrogen   A is CH 2 CH 2 ;   Z is O or NH; and   enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts thereof.   
   
   
       42 . A method of providing analgesia comprising administering to a patient a compound of Formula (I): 
     
       
         
         
             
             
         
       
     
     wherein:
 G is independently selected from —C(Z)N(R 1 )R 2 , phenyl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, C 1-8 alkanyloxy, hydroxy(C 1-8 )alkanyl, carboxy(C 1-8 )alkanyl, C 1-8 alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-8 alkanylthio, aminocarbonyl, aminothiocarbonyl, C 1-8 alkanylaminocarbonyl, di(C 1-8 alkanyl)aminocarbonyl, and C 1-6 alkanyloxycarbonylamino; provided that when G is pyridin-3-yl or thien-3-yl and R 3  is hydrogen, R 4  is other than hydrogen; 
 R 1  is hydrogen or C 1-4 alkanyl; 
 R 2  is selected from the group consisting of hydrogen; C 1-4 alkanyl; phenyl; and C 1-6 cycloalkanyl; wherein C 1-4 alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-4 alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, C 1-8 alkanylaminocarbonyl, di(C 1-8 alkanyl)aminocarbonyl, and phenoxy; and wherein any phenyl-containing substituent of R 2  and C 1-6 cycloalkanyl substituents of R 2  are optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, C 1-8 alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, C 1-8 alkanylthio, C 1-8 alkanylsulfonyl, and C 1-8 alkanylsulfonylamino; or R 1  and R 2  taken together with the nitrogen to which they are attached form a 5-7 membered heterocycloalkyl wherein said heterocycloalkyl is optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, hydroxy(C 1-8 )alkanyl, and hydroxy; 
 R 3  is selected from the group consisting of hydrogen, C 1-8 alkanyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkanyloxy(C 1-8 )alkanyl, C 1-8 alkanylthio (C 1-8 )alkanyl, hydroxyC 1-8 alkanyl, thioformyl, phenylimino(C 1-8 )alkanyl, phenyl(C 1-8 )alkanyl, and heteroaryl(C 1-8 )alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from —O(CH 2 ) 1-3 O—; 
 R 4  is one to three substituents independently selected from the group consisting of hydrogen; C 1-6 alkanyl; C 1-6 alkanyloxy; C 6-10 arylamino wherein C 6-10 aryl is optionally substituted with one to three substitutents independently selected from the group consisting of C 1-6 alkanyl; C 1-6 alkoxy, halogen, and hydroxy; formylamino; pyridinylamino; aminocarbonyl; C 1-6 alkanylaminocarbonyl; C 1-6 alkanylcarbonylamino; halogen; hydroxy; C 6-10 aryl; chromanyl; chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl; naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl; tetrazolyl; thiazolyl; and thienyl; 
 R 5  is one to two substituents independently selected from the group consisting of hydrogen and halogen; 
 A is CH 2 CH 2 ; 
 Y is O; 
 Z is O, NH, N(C 1-6 alkanyl), N(OH), N(OC 1-6 alkanyl), or N(phenyl); and 
 enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts thereof. 
 
   
   
       43 . A method of providing analgesia comprising administering a compound of Formula (I): 
     
       
         
         
             
             
         
       
     
     wherein:
 G is selected from —C(Z)N(R 1 )R 2 , phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-4 alkanyl, C 1-4 alkanyloxy, hydroxy(C 1-4 )alkanyl, carboxy(C 1-4 alkanyl, C 1-4 alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, amino, C 1-6 alkanylamino, di(C 1-6 alkanyl)amino, C 1-8 alkanylthio, aminocarbonyl, aminothiocarbonyl, C 1-8 alkanylaminocarbonyl, and di(C 1-8 alkanyl)aminocarbonyl; 
 R 1  is selected from the group consisting of hydrogen, methyl, ethyl, and propyl; 
 R 2  is selected from the group consisting of hydrogen, C 1-4 alkanyl, phenyl, and C 1-6 cycloalkanyl; wherein C 1-4 alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C 1-4 alkanyloxy, hydroxy, fluoro, aminocarbonyl, C 1-8 alkanylaminocarbonyl, di(C 1-8 alkanyl)aminocarbonyl, and phenoxy; and wherein any phenyl-containing substituent of R 2  is optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyl, C 1-6 alkanyloxy, fluoro, hydroxy, and C 1-6 alkanylthio; or R 1  and R 2  taken together with the nitrogen to which they are attached form pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C 1-3 alkanyl and hydroxy; 
 R 3  is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(C 1-8 )alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group; 
 R 4  is one to two substituents independently selected from the group consisting of hydrogen, C 1-4 alkanyl, C 1-4 alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy; 
 R 5  is hydrogen; 
 A is CH 2 CH 2 ; 
 Y is O; 
 Z is O, NH, or N(OH); and 
 enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts thereof. 
 
   
   
       44 . The method according to  claim 43  wherein G is —C(Z)N(R 1 )R 2 , phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, thienyl, isothiazolyl, isoxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C 1-4 alkanyl, C 1-4 alkanyloxy, hydroxy(C 1-4 )alkanyl, C 1-4 alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl. 
   
   
       44 . The method according to  claim 43  wherein G is —C(Z)N(R 1 )R 2 , 2-methylcarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl. 
   
   
       45 . The method according to  claim 43  wherein G is —C(Z)N(R 1 )R 2 , 1H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl. 
   
   
       46 . The method according to  claim 43  wherein R 2  is selected from the group consisting of hydrogen, C 1-4 alkanyl and phenyl; wherein C 1-4 alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C 1-4 alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent is optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyl, C 1-6 alkanyloxy, fluoro, and hydroxy; or R 1  and R 2  taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from C 1-3 alkanyl or hydroxy; and R 3  is a substituent selected from the group consisting of benzo[1,3]dioxol-5-ylmethyl, carbamimidoyl, 1-H-imidazol-4-ylmethyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxy-ethyl, methoxy-ethyl, 2-methyl-allyl, 2-methyl-but-2-enyl, allyl, furan-3-ylmethyl, H, Me, methylthioethyl, phenethyl, pyridin-2-yl methyl, and thiophen-2-yl methyl. 
   
   
       47 . The method according to  claim 43  wherein R 1  is hydrogen, ethyl, or methyl; R 2  is methyl, ethyl, phenethyl, or hydrogen; or R 1  and R 2  taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-(S)-hydroxypyrrolidin-1-yl. 
   
   
       48 . A method of providing analgesia comprising administering to a patient a compound of Formula (I): 
     
       
         
         
             
             
         
       
     
     wherein:
 G is selected from —C(Z)N(R 1 )R 2 , 2-methylcarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H- [1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H- [1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl; 
 R 1 is hydrogen, methyl, or ethyl; 
 R 2  is selected from the group consisting of hydrogen, C 1-4 alkanyl and phenyl; wherein C 1-4 alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C 1-4 alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R 2  is optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyl, C 1-6 alkanyloxy, fluoro, and hydroxy; or R 1  and R 2  taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from C 1-3 alkanyl or hydroxy; 
 R 3  is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(C 1-8 )alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group; 
 R 4  is one to three substituents independently selected from the group consisting of hydrogen, C 1-4 alkanyl, C 1-4 alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy; 
 R 5  is hydrogen; 
 A is CH 2 CH 2 ; 
 Y is O; 
 Z is O or NH; and 
 
     enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts thereof. 
   
   
       49 . The method according to  claim 48  wherein R 2  is a substituent selected from the group consisting of hydrogen, C 1-4 alkanyl and phenyl; wherein C 1-4 alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C 1-4 alkanyloxy, hydroxy, and 2,6-dimethyl-phenoxy; and wherein any phenyl-containing substituent of R 2  is optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkanyl, C 1-6 alkanyloxy, fluoro, and hydroxy; or R 1  and R 2  taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from C 1-3 alkanyl or hydroxy. 
   
   
       50 . The method according to  claim 48  wherein R 3  is a substituent selected from the group consisting of benzo[1,3]dioxol-5-ylmethyl, carbamimidoyl, 1-H-imidazol-4-ylmethyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxy-ethyl, methoxy-ethyl, 2-methyl-allyl, 2-methyl-but-2-enyl, allyl, furan-3-ylmethyl, H, Me, methylthioethyl, phenethyl, pyridin-2-yl methyl, and thiophen-2-ylmethyl; and R 4  is one to two substituents independently selected from the group consisting of hydrogen, C 1-4 alkanyl, C 1-4 alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy. 
   
   
       51 . The method according to  claim 48  wherein R 3  is a substituent selected from the group consisting of benzo[1,3]dioxol-5-ylmethyl, carbamimidoyl, 1-H-imidazol-4-yl methyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxyethyl, methoxyethyl, allyl, furan-3-yl methyl, H, Me, methylthioethyl, and phenethyl; R 4  is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, α′- or β′-phenyl, α′- or β′-pyridinyl, α′- or β′-furanyl, and hydroxy. 
   
   
       52 . The method according to  claim 48  wherein R 3  is a substituent selected from the group consisting of H, benzo[1,3]dioxol-5-ylmethyl, 1-H-imidazol-4-yl methyl, furan-3-ylmethyl, pyridin-2-ylmethyl, and phenyliminomethyl; and R 4  is a substituent independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, α′- or β′-phenyl, α′- or β′-pyridinyl, α′- or β′-furanyl, and hydroxy. 
   
   
       53 . A method of providing analgesia comprising administering to a patient a compound of Formula (I): 
     
       
         
         
             
             
         
       
       selected from the group consisting of: 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is 1H-imidazol-2-yl-methyl; R 4  is α′-hydroxy; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is furan-3-yl-methyl; R 4  is α′-hydroxy; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is α′-hydroxy; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is α′-methoxy; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is pyridin-2-yl-methyl; R 4  is H; R 5  is H; Y is O; A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is furan-3-yl-methyl; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is thien-2-yl-methyl; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is benzyl; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is pyridin-3-yl; R 3  is furan-3-y1 methyl; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is furan-2-yl methyl; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is α′-methyl; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is α′-phenyl; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is β″-bromo; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is α′-chloro; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is H; R 4  is α′-fluoro; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is 2-methylcarbonylamino-phenyl; R 3  is H; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is pyrrolidin-1-yl; R 3  is H; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is furan-3-yl-methyl; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —; and 
       a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R 3  is furan-3-yl-methyl; R 4  is H; R 5  is H; Y is O; and A is —CH 2 CH 2 —. 
     
   
   
       54 . A method according to  claim 1  wherein the compound is:
 10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   (3 -Hydroxy-pyrrolidin-1-yl)-[10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-yl]-methanone;   10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3 -carboxylic acid methyl-phenethyl-amide;   Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;   Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;   Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;   Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-N,N-diethyl-10H-phenoxazine-3-carboxamidine;   Endo-N,N-Diethyl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine;   Endo-N,N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine;   Endo-3-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-yl]-4H-[1,2,4]oxadiazol-5-one;   endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid amide;   Endo-3-[10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-yl]-4H-[1,2,4]oxadiazol-5-one;   Endo-3-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-yl]-4H-[1,2,4]oxadiazol-5-one;   10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenoxazine-3-carboxylic acid diethylamide;   6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   6-Hydroxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;   N,N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine;   3-[10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-yl]-4H-[1,2,4]oxadiazol-5-one;   10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine;   N-{2-[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-yl]-phenyl}-acetamide;   10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-3-pyridin-3-yl-10H-phenothiazine;   3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine;   10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-3-pyridin-4-yl-10H-phenothiazine;   3-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine; or   3-Pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine.   
   
   
       55 . A method according to  claim 1  wherein the compound is:
 Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;   Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;   Endo-3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;   Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;   Endo-3-Pyridin-3-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;   Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;   Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl- 10H-phenoxazine;   Endo-3-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl-10H-phenoxazine;   Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10-phenoxazine;   Endo-3-Pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;   Exo-3-(3-Pyridin-3-yl-phenoxazine-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester;   Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;   Exo-3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;   Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;   Exo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;   Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;   Exo-3-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;   Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;   Exo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine; or   Exo-3-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3 -yl]-4H-[1,2,4]oxadiazol-5-one;   
   
   
       56 . A method according to  claim 1  wherein the compound is:
 Endo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Exo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Exo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Exo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Exo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;   Exo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Exo-10-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide; or   Exo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide.   
   
   
       57 . A method according to  claim 1  that is:
 Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Exo-10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazine-4-ol;   Endo-7-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-4-ol;   Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-3-yl-10H-phenoxazine;   Endo-6-Methoxy-3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;   Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol;   Endo-7-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-4-ol;   Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazine-4-ol;   Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-4-yl-10H-phenoxazine;   Endo-6-Methoxy-3-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;   Endo-6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;   Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-yl]-phenyl}-acetamide;   Endo-N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-yl]-phenyl}-acetamide;   Endo-N-{2-[10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-yl]-phenyl}-acetamide;   Endo-N-{2-[10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-yl]-phenyl}-acetamide;   Exo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)- 10H-phenoxazine-3-yl]-phenyl}-acetamide;   Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-hydroxy-10H-phenoxazine-3-yl]-phenyl}-acetamide; or   Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenoxazine-3-yl]-phenyl}-acetamide.   
   
   
       58 . A method according to  claim 1  wherein the compound is:
 Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;   Endo-3-[10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-yl]-4H-[1,2,4]oxadiazol-5-one;   Endo-10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-7-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-4-ol;   Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-hydroxy-10H-phenoxazine-3-yl]-phenyl}-acetamide;   Endo-10-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   6-Hydroxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Endo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;   Exo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide   Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazine-4-ol;   Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazine-4-ol; or   Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine.   
   
   
       59 . A method of providing analgesia comprising administering to a patient a composition comprising the dextrorotatory enantiomer of a compound according to  claim 1  wherein said composition is substantially free from the levorotatory isomer of said compound. 
   
   
       60 . A method of providing analgesia comprising administering to a patient a composition comprising the levororotatory enantiomer of a compound according to  claim 1  wherein said composition is substantially free from the dextrorotatory isomer of said compound. 
   
   
       61 . A method of providing analgesia comprising administering to a patient a composition comprising the exo isomer of a compound according to  claim 1  wherein said composition is substantially free from the endo isomer of said compound. 
   
   
       62 . A method of providing analgesia comprising administering to a patient a composition comprising the endo isomer of a compound according to  claim 1  wherein said composition is substantially free from the exo isomer of said compound. 
   
   
       63 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to any of  claims 1  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       64 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 1  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       65 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 42  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       66 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 42  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       67 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 43  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       68 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 43  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       69 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 48  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       70 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 48  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       71 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 53  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       72 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 53  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       73 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 54  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       74 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 54  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       75 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 55  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       76 . A method of providing analgesia comprising administering to a patient veterinary composition comprising a compound, salt or solvate according to  claim 55  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       77 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 59  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       78 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 59  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       79 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 60  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       80 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 60  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       81 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 61  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       82 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 61  admixed with a veterinarily acceptable carrier, excipient or diluent. 
   
   
       83 . A method of providing analgesia comprising administering to a patient a pharmaceutical composition comprising a compound, salt or solvate according to  claim 62  admixed with a pharmaceutically acceptable carrier, excipient or diluent. 
   
   
       84 . A method of providing analgesia comprising administering to a patient a veterinary composition comprising a compound, salt or solvate according to  claim 62  admixed with a veterinarily acceptable carrier, excipient or diluent.